AI exoskeleton gives wheelchair users the freedom to walk again
For Caroline Laubach, being a Wandercraft test pilot is about more than just trying out new technology. It's about reclaiming a sense of freedom and connection that many wheelchair users miss. Laubach, a spinal stroke survivor and full-time wheelchair user, has played a key role in demonstrating the personal AI-powered prototype exoskeleton's development, and her experience highlights just how life-changing this device can be.
"When I'm in the exoskeleton, I feel more free than I do in my daily life," said Laubach. "It gives me the opportunity to walk around and talk to people at eye level. I don't have to look up at people all the time.
"It makes me feel more visible and able to connect with others. One thing I noticed right away, was how inclusive the exoskeleton would be to a wide variety of disabilities. The goal is to have disabled people able to use this exoskeleton to live their daily life out in the world; I can definitely see that happening in the future."
Laubach's story is at the heart of Wandercraft's mission: to help people move through the world with greater walking independence and upright mobility.
Wandercraft's journey began with a personal challenge. Nicolas Simon, the company's co-founder, saw his own family members struggle with mobility due to Charcot-Marie-Tooth disease, a genetic condition. As a student and robotics enthusiast, Simon wanted to create something that could help his brother and others like him walk again. Alongside Matthieu Masselin and Jean-Louis Constanza, who also had a personal connection to the cause, Simon founded Wandercraft in 2012.
Their goal was simple but ambitious: to bring advanced mobility solutions to the estimated 80 million people worldwide who rely on wheelchairs.
Wandercraft's first exoskeleton, Atalante X, is already making a difference in over 100 clinics and research centers worldwide. This device, cleared by the Food and Drug Administration (FDA) and approved in Europe, helps patients take over a million steps each month as part of their rehabilitation. It has already helped hundreds regain some mobility and independence.
But Wandercraft wanted to go further. The new Personal Exoskeleton protoype, now in clinical trials in New York and New Jersey, is designed for daily life, at home, at work, and out in the community. It uses NVIDIA AI to adapt instantly to each user's movements, providing smooth, stable walking on all sorts of surfaces, from sidewalks to carpets. Users control the exoskeleton with a joystick, making it accessible to people with a wide range of abilities.
A big part of Wandercraft's progress comes from its partnership with Nvidia. The team uses Nvidia Isaac Sim, a powerful simulation tool, to test and improve the exoskeleton in virtual environments before real-world trials. They're also exploring Nvidia's healthcare robotics and edge computing platforms to make the device smarter and more responsive.
This technology means the exoskeleton can someday keep up with everyday life, walking at a normal pace, crossing streets, and even handling stairs. As Simon puts it, "It's essential for the exoskeleton to be fast enough that it can be used in the real world. By integrating NVIDIA AI into the device, we can someday enable users to walk at an average pace, cross the road, and go up and down stairs."
Wandercraft's commitment to improving lives goes beyond just building exoskeletons. In the heart of Manhattan, the company has opened Walk in New York by Wandercraft, a state-of-the-art physical therapy practice and Atalante X walk center located at 345 Park Avenue South. This groundbreaking center is the first of its kind in the U.S. and represents a partnership between Wandercraft and licensed physical therapy professionals to help individuals with neurological conditions move more, move better and move again.
At Walk in New York, movement is truly seen as medicine. The center offers personalized screenings with licensed physical therapists, hands-free walking sessions using the Atalante X exoskeleton, and comprehensive neurorehabilitation services. Patients can experience walking again in a safe, professional environment, regardless of their trunk or upper body strength. Each therapy plan is tailored to the individual, and progress is tracked objectively to ensure the best possible outcomes.
The technology at Walk in New York goes beyond exoskeletons. The center features virtual reality systems for real-time movement feedback, mirror therapy to promote motor recovery, advanced gait analysis, and immersive environments that make rehabilitation more engaging and effective.
Walk in New York is also set to become the hub for Wandercraft's Personal Exoskeleton, where individuals will be able to receive their own devices, undergo training, and access ongoing support as this technology becomes available for everyday use. The center's focus on personalized care and innovation makes it a welcoming space for anyone interested in rediscovering mobility, whether for themselves or a loved one.
At Walk in New York, the belief is simple: movement is medicine, and everyone deserves the chance to move through life with confidence and independence.
Wandercraft is working toward FDA approval for the Personal Exoskeleton, with hopes of making it available to millions of wheelchair users in the U.S. and beyond. The company is actively recruiting participants for its clinical trials and is committed to making this technology accessible, with plans for Medicare coverage in the future.
Are you an adult 18 or older with a complete or incomplete motor SCI at or above the T6 vertebra? If so, you might be eligible for our clinical trial. To participate, you'll need a physically able companion to assist you during sessions. If you don't have someone in mind, don't worry, Wandercraft is creating a volunteer network to help connect trial participants with companions. Both patients and companions should be able to speak English or communicate well with a translator. If you meet these criteria, or if you're interested in volunteering as a companion, you can reach out to Wandercraft by emailing them at clinicaltrials@wandercraft.health
Despite all the advances in technology over the past few decades, tens of millions of people still rely on wheelchairs. Wandercraft's Personal Exoskeleton, shaped by the real-life experiences of test pilots like Laubach, is offering a new way forward, one that brings freedom, independence and a renewed sense of possibility.
Laubach's story really shows how powerful this technology can be when it is designed with real people in mind. Wandercraft's Personal Exoskeleton isn't just about robotics or AI; it's about helping people stand tall, connect with others, and live life on their own terms. Every step taken with this device brings that vision closer to reality, making the future of mobility feel more hopeful and within reach than ever before.
In what ways could AI-driven wearable robotics reshape how we think about disability and independence? Let us know by writing us at Cyberguy.com/Contact
For more of my tech tips and security alerts, subscribe to my free CyberGuy Report Newsletter by heading to Cyberguy.com/Newsletter
Follow Kurt on his social channels:
Answers to the most-asked CyberGuy questions:
New from Kurt:
Copyright 2025 CyberGuy.com. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Vista CEO: AI Will Replace 60% of Bankers
Vista Partners CEO Robert Smith is warning from the Berlin SuperReturn Conference that "40% of the people at this conference will have an AI agent and the remaining 60% will be looking for work." Bloomberg Intelligence Senior Banking Analyst Tomasz Noetzel joined Wall Street Beat on Bloomberg Open Interest to talk about his report that shows Wall Street job losses could top two hundred thousand in the age of AI. (Source: Bloomberg)
Medscape
an hour ago
- Medscape
Grass Pollen: A Double Threat to Allergy Patients
Patients with pollen allergy who were exposed to higher concentrations of grass pollen were more likely to have physical symptoms and impairments in day-to-day life. METHODOLOGY: Researchers conducted an observational pilot study to assess the association between daily grass pollen concentrations and physical symptoms and daily life impairments experienced by patients with pollen allergy. The analysis included 53 patients (mean age, 41.8 years; 68% women) with grass pollen-induced allergic rhinitis in Bavaria, Germany, evaluated between May and July 2022. Researchers collected data for the pollen season 2022 from the Electronic Pollen Information Network of Bavaria. An app-based questionnaire was used to collect patients' data on allergic symptoms and treatment measures. They used a physical symptoms index to assess patients' daily eye and nose symptoms and a daily overall impairments index to assess impairments in performance, sleep quality, and activities. TAKEAWAY: The average grass pollen concentration measured between early May and late July 2022 was 37.1 pollen particles/m 3 . . A significant association was observed between grass pollen concentration and both the physical symptoms index (regression coefficient [beta], 0.002; P < .001) and impairments in day-to-day life (beta, 0.00064; P < .048). < .001) and impairments in day-to-day life (beta, 0.00064; < .048). Additionally, pollen levels were significantly associated with performance impairment (beta, 0.0009; P = .027); no significant association was observed with sleep or daily activities. IN PRACTICE: 'To enhance clinical practice, it is essential to address the gap in adequate medical care for pollen allergy patients and prioritize patient education on recognizing and managing allergic rhinitis,' the authors wrote. 'Advancements in technology-assisted self-monitoring could further empower patients in managing their symptoms and understanding the interplay between environmental triggers and allergic complaints,' they added. SOURCE: Jonas Huss, with the Bavarian Health and Food Safety Authority, Munich, Germany, was the corresponding author of the study, which was published online on May 28 in Scientific Reports. LIMITATIONS: The study relied on physician-diagnosed allergies and self-reported patient data. Additionally, the absence of individualized air pollution or weather data, a limited sample size, and strict exclusion criteria further limited the generalizability of the findings. DISCLOSURES: The study was funded by the Bavarian State Ministry of Health and Care. The authors reported having no conflicts of interest.
CNN
an hour ago
- CNN
Morten Harket, lead singer of a-ha, has Parkinson's disease
Morten Harket has revealed he has Parkinson's disease. The singer of a-ha, the band behind the 1985 hit and innovatively animated music video 'Take On Me,' shared the news during an interview with the group's biographer. 'I've got no problem accepting the diagnosis,' Harket said. 'With time, I've taken to heart my 94-year-old father's attitude to the way the organism gradually surrenders: 'I use whatever works'.' Harket, 65, explained why he wanted to share his diagnosis publicly. 'Acknowledging the diagnosis wasn't a problem for me; it's my need for peace and quiet to work that has been stopping me. I'm trying the best I can to prevent my entire system from going into decline,' he said. 'It's a difficult balancing act between taking the medication and managing its side effects. There's so much to weigh up when you're emulating the masterful way the body handles every complex movement, or social matters and invitations, or day-to-day life in general.' According to Mayo Clinic, 'Parkinson's disease is a movement disorder of the nervous system that worsens over time.' Harket had 'advanced brain surgery' at the Mayo Clinic, which along with medication, 'have softened the impact of his symptoms,' the a-ha biographer, Jan Omdahl, wrote. 'In June 2024, Morten underwent a neurosurgical procedure in which electrodes were implanted deep inside the left side of his brain. These are connected to a small pacemaker-like device placed under the skin of the upper chest that sends electrical impulses through the electrodes into the brain,' Omdahl wrote. 'The method is called deep brain stimulation (DBS) and is among the most advanced treatments in neurology. The procedure had the desired effect: with the right electrical impulses now reaching Morten's brain, many of his physical symptoms practically vanished. In December 2024 he underwent a similar procedure on the right side of his brain, which was also successful.' Harket's voice, however, has been affected, he said. 'The problems with my voice are one of many grounds for uncertainty about my creative future,' Harket said.
